Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 25;53(6):715-725.
doi: 10.3724/zdxbyxb-2024-0117.

[Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma]

[Article in Chinese]
Affiliations
Review

[Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma]

[Article in Chinese]
Yuqian Mo et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. .

Abstract

Ferroptosis is a form of regulated cell death, which is dependent on iron metabolism imbalance and characterized by lipid peroxidation. Ferroptosis plays a crucial role in various pathological processes. Studies have shown that the occurrence of ferroptosis is closely associated with the progression of hepatocellular carcinoma (HCC). Ferroptosis is involved in regulating the lipid metabolism, iron homeostasis, mitochondrial metabolism, and redox processes in HCC. Additionally, ferroptosis plays a key role in HCC tumor immunity by modulating the phenotype and function of various immune cells in the tumor microenvironment, affecting tumor immune escape and progression. Ferroptosis-induced lipid peroxidation and oxidative stress can promote the polarization of M1 macrophages and enhance the pro-inflammatory response in tumors, inhibiting immune suppressive cells such as myeloid-derived suppressor cells and regulatory T cells to disrupt their immune suppression function. The regulation of expression of ferroptosis-related molecules such as GPX4 and SLC7A11 not only affects the sensitivity of tumor cells to immunotherapy but also directly influences the activity and survival of effector cells such as T cells and dendritic cells, further enhancing or weakening host antitumor immune response. Targeting ferroptosis has demonstrated significant clinical potential in HCC treatment. Induction of ferroptosis by nanomedicines and molecular targeting strategies can directly kill tumor cells or enhance antitumor immune responses. The integration of multimodal therapies with immunotherapy further expands the application of ferroptosis targeting as a cancer therapy. This article reviews the relationship between ferroptosis and antitumor immune responses and the role of ferroptosis in HCC progression from the perspective of tumor immune microenvironment, to provide insights for the development of antitumor immune therapies targeting ferroptosis.

铁死亡是一种依赖铁代谢失衡并以脂质过氧化为特征的调控性细胞死亡形式,在多种病理过程中发挥关键作用。研究表明,铁死亡的发生与肝细胞癌(HCC)的进展密切相关。铁死亡参与调控HCC的脂质代谢、铁离子稳态、线粒体代谢和氧化还原过程,在HCC肿瘤免疫中发挥着关键作用。铁死亡通过调节免疫微环境中不同细胞的表型和功能影响肿瘤的免疫逃逸和进展;铁死亡诱导的脂质过氧化物和氧化应激能促进M1型巨噬细胞的极化,增强肿瘤的促炎反应,同时抑制髓源性抑制细胞和调节性T细胞等免疫抑制细胞的功能,从而破坏免疫抑制;铁死亡相关分子如谷胱甘肽过氧化物酶4、溶质载体家族7成员11等的表达调控不仅影响肿瘤细胞对免疫治疗的敏感性,也直接作用于T淋巴细胞、树突状细胞等效应细胞的活性和生存,进一步增强或减弱抗肿瘤免疫反应。靶向铁死亡在HCC治疗中展现了重要的临床潜力,通过纳米医学和分子靶向策略诱导铁死亡,不仅直接杀伤肿瘤细胞,还能增强抗肿瘤免疫反应。结合免疫治疗的多模式疗法进一步拓展了铁死亡的应用。本文尝试从代谢调控和免疫细胞调节角度,探讨铁死亡在HCC进展中的作用,以期为开发基于铁死亡调控的综合抗肿瘤治疗策略提供新思路。.

Keywords: Ferroptosis; Hepatocellular carcinoma; Immune microenvironment; Immunotherapy; Review; Tumor immunity.

PubMed Disclaimer

Conflict of interest statement

所有作者均声明不存在利益冲突

The authors declare that there is no conflict of interests

Similar articles

References

    1. BRAY F, LAVERSANNE M, SUNG H, et al. . Global cancer statistics 2022: GLOBOCAN estimates of inci-dence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. 10.3322/caac.21834 - DOI - PubMed
    1. SIEGEL R L, MILLER K D, FUCHS H E, et al. . Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. 10.3322/caac.21708 - DOI - PubMed
    1. WANG K, WANG C, JIANG H, et al. . Combination of ablation and immunotherapy for hepatocellular carci-noma: where we are and where to go[J]. Front Immunol, 2021, 12: 792781. 10.3389/fimmu.2021.792781 - DOI - PMC - PubMed
    1. ZHENG J, KUK D, GÖNEN M, et al. . Actual 10-year survivors after resection of hepatocellular carcinoma[J]. Ann Surg Oncol, 2017, 24(5): 1358-1366. 10.1245/s10434-016-5713-2 - DOI - PMC - PubMed
    1. BODZIN A S, LUNSFORD K E, MARKOVIC D, et al. . Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence charac-teristics[J]. Ann Surg, 2017, 266(1): 118-125. 10.1097/sla.0000000000001894 - DOI - PubMed

MeSH terms

Substances